Do not index
By Karen Rea FNP-BC
If you work with patients carrying shoulder injuries, you know the rotator cuff is one of the most frustrating things in the body to heal. It's a group of four muscles whose tendons wrap around the head of the humerus and keep the shoulder stable through every reach, lift, and rotation. When one of those tendons tears, even partially, the whole joint pays for it: pain, weakness, a night's sleep ruined by lying on the wrong side, and a range of motion that keeps shrinking.
Partial tears are especially maddening. They're common, they get more common with age, and they sit in this awkward middle ground where surgery feels like overkill but conservative care often isn't enough. When physical therapy, anti-inflammatories, and steroid injections run out of road, a lot of patients are left staring down an operation they'd rather avoid.
That's why a case series published in Medicine by Ackley and colleagues caught my eye. It asks a simple, practical question: for partial rotator cuff tears that won't respond to the usual treatments, can a single injection of birth-tissue matrix actually move the needle?
The study, in plain terms
The researchers looked at 10 patients with partial rotator cuff tears that had already failed conservative treatment. These weren't fresh injuries just starting the recovery process; these were people who had tried the standard playbook and were still hurting.
Each patient received a single injection of 50 mg of cryopreserved amniotic membrane and umbilical cord (AM/UC) particulate matrix. Then they were followed for six months and measured three ways: the Penn Shoulder Score (PSS), which captures pain, satisfaction, and function; a range-of-motion exam; and MRI imaging read by a musculoskeletal radiologist who was blinded to the results.
A quick word on why amniotic and umbilical tissue keeps showing up in this literature. Both are rich in anti-inflammatory proteins, growth factors, and extracellular matrix components, and they've been studied across a range of orthopedic indications for their ability to calm inflammation and support healing. The idea here isn't to mask symptoms the way a steroid does, but to deliver biological signals that help the tissue environment recover.
What they found
The patient-reported outcomes were strong.
Overall shoulder scores nearly doubled. The average Penn Shoulder Score climbed from 46.8 out of 100 at baseline to 82.0 at six months. That's not a marginal bump; that's the kind of shift that changes how someone lives day to day.
Pain, function, and satisfaction all improved. Broken into sub-scores, pain improved by 78.4%, function by 82.3%, and satisfaction by 37.1% from baseline.
Range of motion came back almost fully. On average, range of motion went from 77.9% of normal at baseline up to 99.9% at six months.
No adverse events were reported. For a biologic injection, that's a meaningful safety signal worth noting.
The honest caveat
Here's the part I think matters most for those of us who care about doing this work responsibly. The follow-up MRIs did not show a significant change in tear size. Structurally, the tears looked much the same as before.
So how did patients feel so much better while the imaging stayed flat? That disconnect is exactly the kind of thing this field has to keep wrestling with honestly. It may reflect reduced inflammation, improved tissue quality that doesn't fully register on MRI, or changes in how the joint functions that aren't captured by tear dimensions alone. We don't have the answer from a study this size, and I'd be doing you a disservice to pretend otherwise.
And size is the other caveat. Ten patients, no control group, single site. This is preliminary data, full stop. It points to a direction worth studying, not a settled conclusion. The authors frame it that way, and so should we.
Why this matters in practice
What I take from this is cautious optimism, which is honestly where most of the good regenerative literature lives right now. For a patient with a refractory partial tear who wants to exhaust their options before surgery, here's early evidence that a single AM/UC injection was well tolerated and was followed by real, patient-reported gains in pain and function.
But here's the thing I always come back to: a promising therapy is only as good as the hands delivering it. With an injection like this, accurate placement, patient selection, and proper technique are what separate a meaningful result from a disappointing one. The biology can only do its job if it's delivered well.
That's the whole reason I do what I do. The science is moving quickly, and our job is to keep up with it and to deliver it skillfully.
Keep Learning With Us
If this kind of research excites you the way it excites me, I'd love for you to go deeper with our community.
Join us at the Regen Summit. It's where practitioners come together to learn the latest in regenerative medicine, sharpen their clinical thinking, and connect with others who are serious about doing this work at a high level. Whether you're new to the space or already deep in it, you'll leave with practical knowledge you can put to use right away. Lock in your seat at RegenEvent.com.
And come train with us inside My Injection Training. Our Skool platform is built to give you hands-on, confidence-building education in injection technique, the kind of skill development that turns good science into great results for your patients. You can join the community here: skool.com/myinjectiontraining
The future of medicine is regenerative, and the best way to be ready for it is to keep learning. I hope to see you there.
— Karen Rea
This article references: Ackley JF, Kolosky M, Gurin D, Hampton R, Masin R, Krahe D. "Cryopreserved amniotic membrane and umbilical cord particulate matrix for partial rotator cuff tears: A case series." Medicine (Baltimore). 2019 Jul;98(30):e16569. doi:10.1097/MD.0000000000016569. PMID: 31348285. This blog is for educational purposes only and does not constitute medical advice.